Who is sponsoring NCT07034690?

NCT07034690 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT07034690?

Interventions in NCT07034690: Educational Material, Standard of care.

What condition does NCT07034690 study?

NCT07034690 studies Atherosclerotic Cardiovascular Disease.

Is NCT07034690 still recruiting?

NCT07034690 is currently recruiting now. Last updated 30 January 2026.

Last reviewed 2026-01-30 · How we verify

NCT07034690: OPTIMA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia

Recruiting now Phase 4 Last updated 30 January 2026

What this trial tests

Phase 4 trial testing Educational Material in Atherosclerotic Cardiovascular Disease in 326 participants. Currently enrolling.

Timeline

26 November 2025

Primary endpoint
23 June 2026

30 June 2027

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	326
Start date	26 November 2025
Primary completion	23 June 2026
Estimated completion	30 June 2027
Sites	1 location across United Arab Emirates

Drugs / interventions tested

Educational Material
Standard of care

Conditions studied

Atherosclerotic Cardiovascular Disease — all drugs for Atherosclerotic Cardiovascular Disease →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

Adults 18 to 100, any sex, with Atherosclerotic Cardiovascular Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is an open label, randomized, prospective, type I hybrid effectiveness- implementation, pragmatic clinical trial to evaluate the impact of a targeted lipid optimization program on LDL-C control in participants with dyslipidemia who are at high risk or very high risk of cardiovascular events.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Educational Material

Trials testing the same drug.

NCT06348914 — Knowledge of Vital Pulp Therapy in Permanent Teeth Among a Group of Dental Students in Egypt · unknown
NCT03854734 — Healthy, Immunized Communities Study · NA · completed
NCT03405298 — Reducing Inappropriate Benzodiazepine Use Among Older Adults · NA · completed

Other recruiting trials for Atherosclerotic Cardiovascular Disease

Currently open trials in the same condition.

NCT06424860 — Fish Oil, Metformin and Heart Health in PCOS · Phase 1 · recruiting
NCT06962488 — Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure · NA · recruiting
NCT07037433 — Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiov · Phase 3 · recruiting
NCT06875973 — Pelacarsen Roll-over Extension Program · Phase 3 · recruiting
NCT06858332 — Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07034690 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 30 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07034690.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing